Cue Biopharma CUE 深 沪
已收盘 07-18 16:00:00 美东时间
0.90
+0.060
+7.14%
华盛通- 最 高0.975
- 今 开0.8321
- 成交量 49.47万股
- 最 低 0.8225
- 昨 收 0.84
- 总市值 6781.49万
- 52周最高 1.9891
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.45
- 委 比 0.00%
- 总股本 7534.99万
- 历史最高 31.69
- 量 比 0.33
- 振 幅 18.15%
- 历史最低 0.45
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
Cue Biopharma reported additional complete response (CR) in a patient with recurrent metastatic HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and pembrolizumab. The overall response rate (ORR) reached 50% for patients with CPS ≥1, including 50% in low CPS (1-19). Twelve-month overall survival was 88%, and median overall survival (mOS) was 32 months, significantly outperforming historical data. The findings highlight the ...
07-16 12:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Pluri (NASDAQ:PLUR) shares moved upwards by 24.0% to $5.99 during Tues...
07-02 05:05
Cue Biopharma Amends License Agreement with MIL 40G
Cue Biopharma ( ($CUE) ) just unveiled an announcement. On June 30, 2025, Cue B...
07-02 04:43
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
Cue Biopharma的CUE-101药物在治疗HPV+复发性转移性头颈部鳞状细胞癌的临床试验中展现了显著效果，包括50%的总体反应率和88%的12个月生存率，中位总生存期达32个月。该药物通过激活和扩增肿瘤特异性T细胞发挥作用，被视为潜在突破性治疗方法。公司正考虑进一步的战略合作。
07-01 20:05
Cue Biopharma Receives FDA Pre-IND Feedback For Lead Autoimmune Therapy CUE-401; Plans IND Filing Pending Final Studies
Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of
06-25 04:50
CIBC Asset Management announces CIBC ETF cash distributions for June 2025
TORONTO, June 24, 2025 /CNW/ - CIBC (TSX: CM) (NYSE: CM) – CIBC Asset Management Inc. today announced the June 2025 cash distributions for CIBC ETFs and ETF Series of the CIBC Fixed Income P...
06-25 00:00
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
Cue Biopharma receives positive FDA feedback on CUE-401, a first-in-class bispecific fusion protein designed to induce and expand regulatory T cells (Tregs) in vivo through the co-activity of TGF-β and a modified IL-2 variant. The company plans to file an IND after completing final studies. CUE-401 aims to convert autoreactive effector T cells into stable iTregs, offering potential long-lasting immune rebalance for autoimmune and inflammatory dis...
06-24 20:48
Cue Biopharma CFO Resignation and Board Appointment
Cue Biopharma ( ($CUE) ) has shared an update. On June 4, 2025, Cue Biopharma, ...
06-11 04:40
Cue Biopharma CEO Daniel Passeri To Serve As Interim CFO; Kerri-ann Millar Resigns As CFO
- SEC Filing
06-11 04:05
Cue Biopharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $421.00K Miss $1.27M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 32 percent increase over losses of $(0.25) per share from the
05-13 04:49
